Home / Research
Unlike programs focused on illness, Metanoia explores natural psychedelics for personal growth in healthy people — integrating five disciplines for a 360° understanding of how they expand creativity, cognition, and emotional resilience.
Multidisciplinary Research
One question runs through all of them: how do we thrive?
How psychedelics change brain activity, neuroplasticity, and cognition — and what that means for creativity, focus, and emotional resilience in healthy people.
Read moreResearch Focus
Nearly every classic psychedelic — psilocybin, LSD, DMT, mescaline, 5-MeO-DMT — begins with the same molecular handshake: binding to the serotonin 2A receptor (5-HT2A) on brain cells. Block that one receptor and the classic experience disappears. (MDMA is the family's exception, working by releasing serotonin rather than mimicking it.) We study what happens downstream — how that binding loosens the brain's habitual filters and briefly makes the mind more fluid.
The discovery that matters most for our mission is neuroplasticity, and it is strikingly universal. Psilocybin grows new neural connections from inside the cell (Vargas & Olson, 2023); ayahuasca's harmine raises BDNF and spurs new neurons; iboga's ibogaine lifts BDNF and GDNF (MISTIC, Nature Medicine, 2024). Three traditions, three continents, one mechanism — each opening a temporary window in which the brain is unusually ready to form new patterns.
That reframes the whole question for healthy people. If lasting benefit comes partly from a plasticity window, then what you do with it — the integration afterward — may matter as much as the experience itself.
Studying natural sources — mushrooms, cacti, vines, and bark — as whole chemical systems, not single molecules. Each carries an "entourage" of related compounds that may shape the experience.
Read moreResearch Focus
A psilocybin mushroom is not a delivery device for one molecule. It is a chemical system: psilocybin sits alongside its relatives — baeocystin, norbaeocystin, aeruginascin — plus beta-carbolines (the same MAO-inhibitors that power ayahuasca) and aromatic terpenes, all built from the amino acid tryptophan along one short enzymatic pathway.
The central open question is the entourage effect: does the whole source do something an equal dose of the pure molecule does not? The evidence is a ladder — from ethnographic anecdote, up through strong preclinical work, to the first human trial in 2026. And the answer is not the same for every plant: for the mushroom the "whole organism" case is reasonable, but for 5-MeO-DMT the toad's venom carries cardiotoxins and the pure synthetic wins outright. Whole-versus-isolated must be argued organism by organism — and mapping that, honestly, is the work.
The same lens runs across the family — the beta-carbolines that make ayahuasca work, the alkaloids of iboga, the mescaline of cactus. Ethnobotany keeps it rooted: almost everything science "discovered" was known to Indigenous peoples — Mazatec, Zapotec, the Amazon, the Bwiti of Gabon — for centuries. We treat that traditional knowledge as a genuine source, and we hold the ethical debt it implies at the center of the work.
Exploring whether genetic factors influence how individuals respond to psychedelics — a step toward safer, more personalized frameworks for growth.
Read moreResearch Focus
"Genetics" here means two different questions, and keeping them apart clarifies everything. First, the genetics of the mushroom: every species carries the same four-gene pathway, so much of the difference between strains is how strongly those genes are switched on — though real structural variants exist (the Penis Envy strain carries a genuine change in its methylation gene) and true species can differ several-fold in potency.
Second, the genetics of the person — which is where the wild variation lives, and which applies across the whole family. A short cast of liver and gut enzymes breaks these molecules down (the same MAO enzyme that governs whether DMT even works by mouth is a genetic variable too), and the 5-HT2A receptor itself comes in natural variants that alter signalling. Person-to-person response is enormous: in some trials a real fraction of volunteers showed no clear response at all.
The honest state of the field: no human study has yet tied a specific genotype to the strength of a psychedelic experience — with psilocybin, LSD, or anything else. That gap is precisely the opportunity: a step toward safer, more personalized frameworks for growth, across every substance in the family.
Developing evidence-based frameworks for preparation, the experience itself, and integration — including the role of set, setting, and meditation.
Read moreResearch Focus
The molecule is only half the story. Decades of evidence — and thousands of years of tradition — say that set and setting, the state of mind and the surroundings, are not soft add-ons but primary determinants of whether an experience heals or harms. Every tradition understood this: the Mazatec velada with its mushrooms, the Amazonian ayahuasca ceremony, the Bwiti iboga initiation — each is a whole container, not just a dose.
We develop evidence-based frameworks for the whole arc, across substances: preparation (intention, screening, safety — including the hard interactions, like ayahuasca with SSRIs or iboga's cardiac risk), the experience itself (support, music, the role of a sitter), and — critically — integration afterward, the work of turning insight into lasting change. If a plasticity window is real, integration is where its value is either captured or lost.
A firm boundary: Metanoia conducts and shares research and education. We do not supply controlled substances, and we are transparent about our methods and our limits.
How growing conditions, species, and strain shape a source's real chemistry — the origin of the fortyfold potency gap that makes reproducible research possible or impossible.
Read moreResearch Focus
Potency is not a fixed property of a species — it is an outcome of how the organism was grown. Analyses find variation of up to fortyfold between mushroom samples, which turns cultivation from a hobbyist footnote into a scientific variable. You cannot study what you cannot standardize, and you cannot dose safely what you cannot measure.
Substrate, species and strain, environmental conditions, and the moment of harvest all shape the final chemical profile — not only psilocybin, but the entire entourage of related compounds that travel with it. The same logic extends across the family: the alkaloid content of an iboga root or a mescaline cactus depends on age, growing conditions, and provenance.
This discipline also carries our sustainability commitment. We prioritize cultivable sources over threatened or wild ones — peyote is under real ecological pressure, and iboga's demand has consequences in Gabon. Understanding cultivation is how a field grows without consuming the traditions and ecosystems it came from.
Research Focus
Five disciplines, pointed at twelve dimensions of human potential. These are the outcomes our research sets out to understand — and expand.
Expanding human consciousness — studied rigorously, shared openly.
The Measurement Problem
The dimensions above are what our research sets out to understand. There is an awkward problem with that: the field has no common instrument for measuring any of them over time. This is the least glamorous gap in psychedelic science, and we think it is the most important one.
A 2024 systematic review in the Journal of Psychopharmacology examined 93 clinical trials of classic psychedelics and found 17 different rating scales in use across them. Its authors called for the field to develop a core outcome set — a common minimum that every study reports — and recommended that instruments be designed to assess the setting of an experience. Neither exists yet.
There is a second gap underneath the first. Nearly every validated instrument in the field measures the acute experience: what happened during the hours the substance was active. Very little measures what a person was actually seeking, or whether they found it, a month or a year later. For a field increasingly asked to justify itself with durable outcomes, that is a strange place to be.
The consequence shows up plainly in the research. In the largest prospective study of naturalistic psilocybin use published to date, participants overwhelmingly reported using it for "self-exploration" — and their outcomes were measured on scales for anxiety, depression, and alcohol misuse. Clinical instruments pointed at a question that was never clinical. That same study found that 11% of participants at two to four weeks, and 7% at two to three months, reported persisting negative effects — roughly one person in nine — with no standard anywhere for how such an effect should be defined, timed, or recorded.
So results cannot be pooled across studies, benefits cannot be compared, and harms cannot be counted properly. Every new dataset arrives in its own dialect.
Three pieces, all of them plumbing rather than headline science:
All of it will be published openly and free of charge, with no licence fee and no restriction on use, for researchers, state programmes, registries, and clinicians to adopt or adapt. We are also preparing this material as a formal comment to the U.S. Food and Drug Administration, which has asked publicly for exactly this kind of input on common data elements and adverse-event reporting.
A word on what this is not. We are not claiming to be an authority, and a measure is not made legitimate by being announced. It earns its place by being used, tested, and criticised until either it survives or something better replaces it. So we publish drafts rather than verdicts, we invite people to take them apart, and we will say plainly where we got it wrong. Metanoia is well suited to this particular job for one structural reason: we sell nothing to the people our research informs, so no finding is worth more to us than any other.
The Family We Study
Psilocybin is where we began — but the classic psychedelics are a whole family, and Metanoia's research and education are meant to span all of them. Our emphasis is the natural psychedelics; we cover the two classic synthetics for a complete picture. A dedicated book and research program is planned for each.
Our first book and research focus — the mushroom read as a whole chemical system.
The peyote and San Pedro cacti — among the oldest psychedelics known.
A powerful tryptamine from certain plants and the Sonoran Desert toad.
Ongoing Projects
Four initiatives that turn scattered global knowledge into something people can actually use.
A continuously updated, science-based library of psychedelic research results — drawn only from trusted, verified sources, and searchable by anyone.
Read moreOngoing Project
The science of psychedelics is scattered — across journals, languages, preprints, and paywalls — and most of it never reaches the people who could use it. We are building a single, continuously updated library that gathers verified research results into one place, searchable by anyone, free of charge.
The discipline is strict: every entry is drawn only from trusted, verified sources, with the link and the claim checked to match. Nothing fabricated, nothing exaggerated. Where the evidence is strong we say so; where it is thin or contested, we say that too — because an honest map of what we don't yet know is as valuable as a map of what we do.
This is core to Metanoia's mission: turning complex, fragmented research into knowledge people can actually understand and act on.
Ask any question about the safe and responsible use of psychedelics and get an answer grounded in the most current research.
Read moreOngoing Project
Reliable, non-judgmental information about the safe and responsible use of psychedelics is scattered and often drowned out by hype or fear. We are building an AI guide that answers plain-language questions — about interactions, contraindications, set and setting, dose and variability — with responses grounded in the most current, verified research.
It is designed around harm reduction and honesty, not promotion. It will flag real risks clearly: the danger of combining psychedelics with certain antidepressants or MAO-inhibitors, the contraindication for those with a personal or family history of psychosis, and the simple fact that a gram is a weak predictor of strength.
A firm boundary: this is education, not a supply service or a substitute for medical advice.
A global system for collecting, analyzing, and learning from lived psychedelic experiences — historical and ongoing.
Read moreOngoing Project
For decades, people have written careful, first-hand accounts of their psychedelic experiences — a vast, largely untapped record of what these substances actually do in real lives, across cultures and eras. We are building a system to collect, structure, and learn from that record, historical and ongoing.
Lived experience is not a substitute for controlled science, and we never treat it as one. But at scale, and analyzed carefully, it can surface patterns worth studying: which settings tend toward difficulty, how different species or doses are described, how integration shapes lasting outcomes. It is the qualitative counterpart to the research database.
Collected with consent and privacy at the center, this becomes a bridge between the anecdotal and the rigorous.
A common data element set and an outcome measure anchored to purpose — so that results from different studies, programmes, and registries can finally be compared.
Read moreOngoing Project
A 2024 review of 93 clinical trials found 17 different rating scales in use, and called for a core outcome set that does not yet exist. Almost every validated instrument in the field measures the acute experience rather than the durable outcome, and none is designed for what a person was actually seeking. The result is that studies cannot be pooled, benefits cannot be compared, and harms cannot be counted properly.
We are drafting three pieces of plumbing: a minimum common data element set for any record of a psychedelic experience; an outcome measure built on our twelve dimensions and anchored to the purpose a person records before the experience rather than recalls after it; and a standard case definition, with fixed observation windows, for persisting adverse effects.
All of it will be published openly and free, with no licence fee and no restriction on use. We are also preparing it as a formal comment to the U.S. Food and Drug Administration, which has asked publicly for input on exactly these questions.
We are not claiming to be an authority. A measure earns its place by being used and criticised, not announced — so we publish drafts, invite people to take them apart, and say where we got it wrong.
Why Now
After decades in the margins, psychedelic science is having its most consequential moment. Metanoia's job is to translate that moment honestly — and to ask what it means not for illness, but for growth.
Multiple large trials of psilocybin and related compounds have reported results in leading journals, and in 2026 U.S. regulators granted their first priority reviews for psychedelic therapies. The evidence is real, still debated, and evolving month to month.
Reported in JAMA Psychiatry, Nature Medicine, and JAMA Network Open (2024–2026).
Across four countries, roughly one in five adults reports having used a psychedelic — yet only 10–20% ever spoke to a clinician, and over a third of past-year users reported a difficult effect. People are already using these substances. Reliable, science-based guidance has not kept pace.
International Journal of Drug Policy (2026), four-country survey.
Nearly all of this research targets diagnosed illness. The everyday, healthy person seeking growth, creativity, or self-understanding sits almost entirely outside the studies — and outside the safeguards. That gap is Metanoia's reason to exist.
Metanoia focus area · see our approach.
One Mechanism, Many Traditions
Three of the world's great psychedelic traditions — the psilocybin mushrooms of Mesoamerica, the iboga of the Gabonese Bwiti, and the ayahuasca of the Amazon — grew up entirely apart from one another. Yet modern neuroscience keeps arriving at the same place when it asks how they work: neuroplasticity, the brain's capacity to reorganize and form new connections.
Psilocybin appears to promote new synaptic growth; the beta-carbolines in ayahuasca raise BDNF, a protein central to neural growth; ibogaine lifts both BDNF and GDNF. Different molecules, different continents, different ceremonies — converging on one biological idea. For a foundation devoted to growth rather than repair, that convergence is more than elegant. It is the ground we build on.
Mechanistic work incl. Vargas & Olson (neuroplasticity); Palhano-Fontes et al. (ayahuasca RCT); MISTIC, Nature Medicine (ibogaine). Presented as education, not medical advice.
All Metanoia research follows applicable laws and ethical guidelines, with advisory oversight and clear approval processes. We're transparent about our methods and our limits — especially given the sensitive nature of this field. Metanoia conducts and shares research and education; we do not supply controlled substances.